icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Failure to multiple Interferon-free direct Antiviral therapies: could Chronic hepatitis C become incurable?
 
 
  Reported by Jules Levin
AASLD 2017 Wash DC October 20-24
 
Download the PDF here
 
Johannes Vermehren1, Julia Dietz1, Simone Susser1, Eckart Schott2, Jörn M. Schattenberg3, Eugen Zizer4, Julian Schulze zur Wiesch5, Christoph Antoni6, Perdita Wietzke-Braun7, Claus Niederau8, Stefan Mauss9, Jurgen K. Rockstroh10, Beat Mullhaupt11, Rudolf E. Stauber12, Stefan Zeuzem1, Christoph Sarrazin1,13; 1Medizinische Klinik 1,
 
Universitatsklinikum Frankfurt, Frankfurt am Main, Germany; 2Charité Universitatsmedizin Berlin, Berlin, Germany; 3Universitatsklinikum Mainz, Mainz, Germany; 4Universitatsklinikum Ulm, Ulm, Germany; 5Universitatsklinikum Eppendorf, Hamburg, Germany; 6Universitatsklinikum Mannheim, Mannheim, Germany; 7Universitatsklinikum Schleswig-Holstein, Kiel, Germany; 8Katholisches Klinikum Oberhausen, Oberhausen, Germany; 9Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 10Universitatsklinikum Bonn, Bonn, Germany; 11Universitatsspital Zurich, Zurich, Switzerland; 12Medizinische Universitat Graz, Graz, Austria; 13St Josefs Hospital, Wiesbaden, Germany
 
AASLD: Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and Clinical Isolates From Direct-Acting Antiviral-Experienced and -Naïve Patients - (10/26/17)
 
AASLD: SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study - (10/23/17)

1127171

1127172

1127173

1127174

1127175